Vitamin A

Doris Benbrook, Ph.D., named Associate Director for Translational Research at OU Health Stephenson Cancer Center, will oversee planning and initiatives to translate basic science discoveries into clinical trials, aiming for NCI Comprehensive Designation. Benbrook, with over 30 years of research experience at OU College of Medicine, developed a new drug, OK-1, entirely in Oklahoma, marking a historic first for the state.

A physician reflects on a patient's admiration for RFK Jr., discussing the FDA's role in public health, the efficacy and safety of psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelation, ivermectin, hydroxychloroquine, vitamins, and nutraceuticals. The article concludes with concerns over RFK Jr.'s potential impact on public health if he were to lead the Department of Health and Human Services, emphasizing the importance of evidence-based medicine and regulatory oversight.

Alkeus Pharmaceuticals' gildeuretinol (ALK-001) received Rare Pediatric Disease and Fast Track designations from the FDA for treating Stargardt disease. Gildeuretinol, designed to reduce vitamin A dimerization, showed efficacy in slowing retinal lesion growth and maintaining visual acuity in early-stage patients, with a favorable safety profile.

Belite Bio announced financial results for Q3 2024, progress in Tinlarebant trials for Stargardt disease and geographic atrophy, appointment of Dr. Hendrik P.N. Scholl as CMO, and an anticipated interim analysis for the DRAGON trial by end of 2024 or early 2025.

Winter increases risk of colds, flu, COVID-19, and RSV due to indoor gatherings and cold, dry conditions. Preventive measures include hand washing, avoiding face touching, adequate sleep, and a healthy diet. Essential vitamins and minerals for immune support include Vitamin A, B9, B12, C, D, iron, and zinc, best obtained through varied food sources. Vitamin D deficiency can increase cold susceptibility, while other deficiencies may cause fatigue, hair loss, or mood disorders.

Christine N. Kay, MD, presented TEASE clinical trial findings on gildeuretinol (ALK-001) for Stargardt disease at the AAO Meeting, showing a 21% reduction in atrophic lesion growth. Gildeuretinol, an oral vitamin A-derived drug, aims to slow disease progression and has FDA orphan drug and breakthrough designations, with further data expected in 2025.

Alkeus Pharmaceuticals to present results from gildeuretinol studies for geographic atrophy and Stargardt disease at AAO 2024 in Chicago.

Retinol, a retinoid from Vitamin A, is FDA-approved for treating acne and photo-aging but can cause side effects like itching, redness, and peeling, known as retinization. Consistency in use reduces these effects, and starting retinol in the 20s or 30s is recommended for anti-aging benefits.

Drugs increasing vitamin A may help treat motor neurone disease (MND), according to Scottish research. These drugs target cells activating vitamin A, potentially slowing brain deterioration. Early signs include muscle twitches, weak grip, and slurred speech. There's no cure, but treatments aim to reduce impact. The study, published in Frontiers in Neuroscience, suggests new drug targets for future therapies.